Evaluation of a DGP Point-of-care Test for Celiac Disease in a Pediatric Population

Claude-Olivier Marti^{1, 2,} , Benoit Fellay¹, Annemarie Bürgin-Wolff³, Jean-Luc Magnin¹ and Peter Baehler¹

¹Hôpital Cantonal Fribourg, Fribourg, Switzerland

²Laboratoire Promed, Marly Switzerland

³Coeliakie Institut, Liestal, Switzerland

Cite this paper:
Claude-Olivier Marti, Benoit Fellay, Annemarie Bürgin-Wolff, Jean-Luc Magnin and Peter Baehler. Evaluation of a DGP Point-of-care Test for Celiac Disease in a Pediatric Population. International Journal of Celiac Disease. 2015; 3(1):7-11. doi: 10.12691/ijcd-3-1-8

Abstract

Celiac disease (CD) is a largely undiagnosed immune-mediated enteropathy. A point-of-care test (POCT) could represent a rapid and cost-effective tool on ruling out CD. The objective of this study is to evaluate retrospectively the performance of a POCT based on detection of IgA and IgG antibodies against deamidated gliadins peptides (DGP). The study was performed on 53 children presenting clinical suspicions of CD, all being investigated by intestinal biopsy and standard serology. The performance of POCT was compared to the diagnostic result obtained from the gold standard of histology and serology. 10 children were diagnosed as CD positive by the POCT. Among the 43 children identified as CD negatives, 37 were correctly identified by POCT and 6 were considered as false positives. No false negative results were observed. The POCT yields a sensitivity and a negative predictive value (NPV) of 100%, and a negative likelihood ratio (LR-) of 0 in this selected pediatric population. The high NPV and low LR- ratio indicate that this POCT could be an useful and discriminative tool for excluding CD. This study and the results published so far are promising but need to be confirmed in larger cohort.

Keywords:
rule-out CD rapid test children

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]	A. Fasano, I. Berti, T. Gerarduzzi, T. Not, R.B. Colletti, S. Drago, Y. Elitsur, P.H. Green, S. Guandalini, I.D. Hill, M. Pietzak, A. Ventura, M. Thorpe, D. Kryszak, F. Fornaroli, S.S. Wasserman, J.A. Murray, K. Horvath, Prevalence of celiac disease in at-risk and not-at-risk groups in the United States: a large multicenter study. Arch Intern Med 163 (2003) 286-292.
[2]	S. Husby, S. Koletzko, I.R. Korponay-Szabo, M.L. Mearin, A. Phillips, R. Shamir, R. Troncone, K. Giersiepen, D. Branski, C. Catassi, M. Lelgeman, M. Maki, C. Ribes-Koninckx, A. Ventura, K.P. Zimmer, European Society for Pediatric Gastroenterology, Hepatology, and Nutrition guidelines for the diagnosis of coeliac disease. J Pediatr Gastroenterol Nutr 54 (2012) 136-160.
[3]	A. Fasano, C. Catassi, Clinical practice. Celiac disease. N Engl J Med 367 (2012) 2419-2426.
[4]	N. Gujral, H.J. Freeman, A.B. Thomson, Celiac disease: prevalence, diagnosis, pathogenesis and treatment. World J Gastroenterol 18 (2012) 6036-6059.
[5]	B. Meresse, G. Malamut, N. Cerf-Bensussan, Celiac disease: an immunological jigsaw. Immunity 36 (2012) 907-919.
[6]	W. Kratzer, M. Kibele, A. Akinli, M. Porzner, B.O. Boehm, W. Koenig, S. Oeztuerk, R.A. Mason, R. Mao, M.H. Haenle, Prevalence of celiac disease in Germany: A prospective follow-up study. World J Gastroenterol 19 (2013) 2612-2620.
[7]	A. Parnanen, K. Kaukinen, S. Helakorpi, A. Uutela, M.L. Lahdeaho, H. Huhtala, P. Collin, M. Maki, K. Kurppa, Symptom-detected and screen-detected celiac disease and adult height: a large cohort study. Eur J Gastroenterol Hepatol 24 (2012) 1066-1070.
[8]	R. Rutz, E. Ritzler, W. Fierz, D. Herzog, Prevalence of asymptomatic celiac disease in adolescents of eastern Switzerland. Swiss Med Wkly 132 (2002) 43-47.
[9]	T. Pozo-Rubio, A. Capilla, J.R. Mujico, G. de Palma, A. Marcos, Y. Sanz, I. Polanco, M.D. Garcia-Novo, G. Castillejo, C. Ribes-Koninckx, V. Varea, F. Palau, L. Ortigosa, L. Pena-Quintana, E. Nova, Influence of breastfeeding versus formula feeding on lymphocyte subsets in infants at risk of coeliac disease: the PROFICEL study. Eur J Nutr 52 (2013) 637-646.
[10]	T. Pozo-Rubio, M. Olivares, E. Nova, G. De Palma, J.R. Mujico, M.D. Ferrer, A. Marcos, Y. Sanz, Immune development and intestinal microbiota in celiac disease. Clin Dev Immunol 2012 (2012) 654143.
[11]	A. Burgin-Wolff, B. Mauro, H. Faruk, Intestinal biopsy is not always required to diagnose celiac disease: a retrospective analysis of combined antibody tests. BMC Gastroenterol 13 (2013) 19.
[12]	S. Amarri, P. Alvisi, R. De Giorgio, M.C. Gelli, R. Cicola, F. Tovoli, R. Sassatelli, G. Caio, U. Volta, Antibodies to Deamidated Gliadin Peptides: An Accurate Predictor of Coeliac Disease in Infancy. J Clin Immunol (2013).
[13]	M. Ankelo, V. Kleimola, S. Simell, O. Simell, M. Knip, E. Jokisalo, M. Tarkia, A. Westerlund, Q. He, M. Viander, J. Ilonen, A.E. Hinkkanen, Antibody responses to deamidated gliadin peptide show high specificity and parallel antibodies to tissue transglutaminase in developing coeliac disease. Clin Exp Immunol 150 (2007) 285-293.
[14]	K. Giersiepen, M. Lelgemann, N. Stuhldreher, L. Ronfani, S. Husby, S. Koletzko, I.R. Korponay-Szabo, Accuracy of diagnostic antibody tests for coeliac disease in children: summary of an evidence report. J Pediatr Gastroenterol Nutr 54 (2012) 229-241.
[15]	E. Liu, M. Li, L. Emery, I. Taki, K. Barriga, C. Tiberti, G.S. Eisenbarth, M.J. Rewers, E.J. Hoffenberg, Natural history of antibodies to deamidated gliadin peptides and transglutaminase in early childhood celiac disease. J Pediatr Gastroenterol Nutr 45 (2007) 293-300.
[16]	E. Schwertz, F. Kahlenberg, U. Sack, T. Richter, M. Stern, K. Conrad, K.P. Zimmer, T. Mothes, Serologic assay based on gliadin-related nonapeptides as a highly sensitive and specific diagnostic aid in celiac disease. Clin Chem 50 (2004) 2370-2375.
[17]	L.A. Mizen, M.L. Macfie, L. Findlay, S.A. Cooper, C.A. Melville, Clinical guidelines contribute to the health inequities experienced by individuals with intellectual disabilities. Implement Sci 7 (2012) 42.
[18]	C.C. Bekebil F, Anghel SI, Besson Duvanel C, Schappi MG, Diagnostic accuracy of a new point-of-care screening assay for celiac disease. World J Gastroenterol in press (2013).
[19]	F. Bienvenu, C. Besson Duvanel, C. Seignovert, P. Rouzaire, A. Lachaux, J. Bienvenu, Evaluation of a point-of-care test based on deamidated gliadin peptides for celiac disease screening in a large pediatric population. Eur J Gastroenterol Hepatol 24 (2012) 1418-1423.
[20]	G. Oberhuber, G. Granditsch, H. Vogelsang, The histopathology of coeliac disease: time for a standardized report scheme for pathologists. Eur J Gastroenterol Hepatol 11 (1999) 1185-1194.
[21]	I. Brusca, A. Carroccio, E. Tonutti, D. Villalta, R. Tozzoli, M. Barrale, F.M. Sarullo, P. Mansueto, S.M. Chiusa, G. Iacono, N. Bizzaro, The old and new tests for celiac disease: which is the best test combination to diagnose celiac disease in pediatric patients? Clin Chem Lab Med 50 (2012) 111-117.
[22]	E. Tonutti, D. Visentini, A. Picierno, N. Bizzaro, D. Villalta, R. Tozzoli, G. Kodermaz, A. Carroccio, G. Iacono, S. Teresi, S.M. La Chiusa, I. Brusca, Diagnostic efficacy of the ELISA test for the detection of deamidated anti-gliadin peptide antibodies in the diagnosis and monitoring of celiac disease. J Clin Lab Anal 23 (2009) 165-171.
[23]	M. Ravikumara, V.K. Nootigattu, B.K. Sandhu, Ninety percent of celiac disease is being missed. J Pediatr Gastroenterol Nutr 45 (2007) 497-499.
[24]	K. Kaukinen, K. Lindfors, P. Collin, O. Koskinen, M. Maki, Coeliac disease--a diagnostic and therapeutic challenge. Clin Chem Lab Med 48 (2010) 1205-1216.
[25]	P.H. Green, A.I. Neugut, A.J. Naiyer, Z.C. Edwards, S. Gabinelle, V. Chinburapa, Economic benefits of increased diagnosis of celiac disease in a national managed care population in the United States. J Insur Med 40 (2008) 218-228.
[26]	P.H.R. Green, S.N. Stavropoulos, S.G. Panagi, S.L. Goldstein, D.J. McMahon, H. Absan, A.I. Neugut, Characteristics of adult celiac disease in the USA: results of a national survey. Am J Gastroenterol 96 (2001) 126-131.
[27]	E. Sugai, H. Vazquez, F. Nachman, M.L. Moreno, R. Mazure, E. Smecuol, S. Niveloni, A. Cabanne, Z. Kogan, J.C. Gomez, E. Maurino, J.C. Bai, Accuracy of testing for antibodies to synthetic gliadin-related peptides in celiac disease. Clin Gastroenterol Hepatol 4 (2006) 1112-1117.
[28]	K. Conrad, D. Roggenbuck, A. Ittenson, D. Reinhold, T. Buettner, M.W. Laass, A new dot immunoassay for simultaneous detection of celiac specific antibodies and IgA-deficiency. Clin Chem Lab Med 50 (2012) 337-343.
[29]	M. Barak, O. Rozenberg, P. Froom, M. Grinberg, D. Reginashvili, C. Henig, A. Pacht, A. Lerner, Challenging our serological algorithm for celiac disease (CD) diagnosis by the ESPGHAN guidelines. Clin Chem Lab Med 51 (2013) e257-259.
[30]	P.D. Mooney, M. Kurien, D.S. Sanders, Simtomax, a novel point of care test for coeliac disease. Expert Opin Med Diagn 7 (2013) 645-651.